Royalty Pharma shares surge 59% after $2.2 billion IPO

Biopharma initial public offerings are back with a bang after a coronavirus pandemic lull, as Royalty Pharma raised a record-breaking $2.2 billion from the sale of 77 million s

Celgene investors’ CVR payment looks rocky, as FDA rejects i...

The chances of former shareholders in Celgene missing out on the big pay-out from their contingent value right (CVR) deal with Bristol-Myers Squibb have risen sharply, aft

COVID-19 candidate Actemra helps Roche to solid first quarte...

Bill Gates slams Trump move to cut WHO funding over coronavi...

J&J lowers 2020 forecast on COVID-19 uncertainty

Takeda eyes emerging markets asset sale to trim its debt; re...